Literature DB >> 24666336

Neutrophils from vasculitis patients exhibit an increased propensity for activation by anti-neutrophil cytoplasmic antibodies.

S M Ohlsson1, S Ohlsson, D Söderberg, L Gunnarsson, Å Pettersson, M Segelmark, T Hellmark.   

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) are thought to be pathogenic in ANCA-associated vasculitis (AAV) by stimulating polymorphonuclear leucocytes (PMNs) to degranulate and produce reactive oxygen species (ROS). The aim of this study was to investigate if PMNs from AAV patients are stimulated more readily by ANCA compared with PMNs from healthy controls (HCs). Differences in ANCA characteristics that can account for different stimulation potential were also studied. PMNs from five AAV patients and five HCs were stimulated with 10 different immunoglobulins (Ig)Gs, purified from PR3-ANCA-positive patients, and ROS production, degranulation and neutrophil extracellular trap (NET) formation was measured. ANCA levels, affinity and clinical data of the AAV donors were recorded. The results show that PMNs from AAV patients produce more intracellular ROS (P = 0·019), but degranulate to a similar extent as PMNs from HCs. ROS production correlated with NET formation. Factors that may influence the ability of ANCA to activate PMNs include affinity and specificity for N-terminal epitopes. In conclusion, our results indicate that PMNs from AAV patients in remission behave quite similarly to HC PMNs, with the exception of a greater intracellular ROS production. This could contribute to more extensive NET formation and thus an increased exposure of the ANCA autoantigens to the immune system.
© 2014 British Society for Immunology.

Entities:  

Keywords:  ANCA-associated vasculitis; autoimmunity; degranulation; reactive oxygen species

Mesh:

Substances:

Year:  2014        PMID: 24666336      PMCID: PMC4008980          DOI: 10.1111/cei.12301

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Hydrocortisone-induced inhibition of reactive oxygen species by polymorphonuclear neutrophils.

Authors:  P Dandona; M Suri; W Hamouda; A Aljada; Y Kumbkarni; K Thusu
Journal:  Crit Care Med       Date:  1999-11       Impact factor: 7.598

2.  A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis.

Authors:  V Witko-Sarsat; P Lesavre; S Lopez; G Bessou; C Hieblot; B Prum; L H Noël; L Guillevin; P Ravaud; I Sermet-Gaudelus; J Timsit; J P Grünfeld; L Halbwachs-Mecarelli
Journal:  J Am Soc Nephrol       Date:  1999-06       Impact factor: 10.121

3.  Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.

Authors:  Aleeza J Roth; Joshua D Ooi; Jacob J Hess; Mirjan M van Timmeren; Elisabeth A Berg; Caroline E Poulton; JulieAnne McGregor; Madelyn Burkart; Susan L Hogan; Yichun Hu; Witold Winnik; Patrick H Nachman; Coen A Stegeman; John Niles; Peter Heeringa; A Richard Kitching; Stephen Holdsworth; J Charles Jennette; Gloria A Preston; Ronald J Falk
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

4.  Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA).

Authors:  Jia Jin Yang; Gloria A Preston; David A Alcorta; Iwao Waga; William E Munger; Susan L Hogan; Stephen B Sekura; Brian D Phillips; Robin P Thomas; J Charles Jennette; Ronald J Falk
Journal:  Kidney Int       Date:  2002-11       Impact factor: 10.612

5.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.

Authors:  Hong Xiao; Peter Heeringa; Peiqi Hu; Zhi Liu; Minglang Zhao; Yasuaki Aratani; Nobuyo Maeda; Ronald J Falk; J Charles Jennette
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

6.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

Authors:  R J Falk; R S Terrell; L A Charles; J C Jennette
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

7.  Identification of human cysteine-rich secretory protein 3 (CRISP-3) as a matrix protein in a subset of peroxidase-negative granules of neutrophils and in the granules of eosinophils.

Authors:  Lene Udby; Jero Calafat; Ole E Sørensen; Niels Borregaard; Lars Kjeldsen
Journal:  J Leukoc Biol       Date:  2002-09       Impact factor: 4.962

8.  Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo.

Authors:  E Csernok; M Ernst; W Schmitt; D F Bainton; W L Gross
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

9.  Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteins.

Authors:  D Selga; M Segelmark; J Wieslander; L Gunnarsson; T Hellmark
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

10.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11
View more
  17 in total

1.  Circulating mitochondrial DNA in serum of patients with granulomatosis with polyangiitis.

Authors:  M P Surmiak; M Hubalewska-Mazgaj; K Wawrzycka-Adamczyk; W Szczeklik; J Musiał; M Sanak
Journal:  Clin Exp Immunol       Date:  2015-05-24       Impact factor: 4.330

Review 2.  An update on the role of epigenetics in systemic vasculitis.

Authors:  Patrick Coit; Haner Direskeneli; Amr H Sawalha
Journal:  Curr Opin Rheumatol       Date:  2018-01       Impact factor: 5.006

Review 3.  The role of neutrophils in rheumatic disease-associated vascular inflammation.

Authors:  Lihui Wang; Raashid Luqmani; Irina A Udalova
Journal:  Nat Rev Rheumatol       Date:  2022-01-17       Impact factor: 20.543

Review 4.  Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases.

Authors:  Gustaf Wigerblad; Mariana J Kaplan
Journal:  Nat Rev Immunol       Date:  2022-10-18       Impact factor: 108.555

5.  Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis.

Authors:  Adrian Schreiber; Anthony Rousselle; Jan Ulrich Becker; Anne von Mässenhausen; Andreas Linkermann; Ralph Kettritz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-24       Impact factor: 11.205

6.  Synthesis and Biological Evaluation of an Indazole-Based Selective Protein Arginine Deiminase 4 (PAD4) Inhibitor.

Authors:  Caroline Chandra Tjin; Rebecca F Wissner; Haya Jamali; Alanna Schepartz; Jonathan A Ellman
Journal:  ACS Med Chem Lett       Date:  2018-09-14       Impact factor: 4.345

7.  IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.

Authors:  C Sandin; P Eriksson; M Segelmark; T Skogh; A Kastbom
Journal:  Clin Exp Immunol       Date:  2016-02-25       Impact factor: 4.330

8.  Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.

Authors:  Huw D Lewis; John Liddle; Jim E Coote; Stephen J Atkinson; Michael D Barker; Benjamin D Bax; Kevin L Bicker; Ryan P Bingham; Matthew Campbell; Yu Hua Chen; Chun-Wa Chung; Peter D Craggs; Rob P Davis; Dirk Eberhard; Gerard Joberty; Kenneth E Lind; Kelly Locke; Claire Maller; Kimberly Martinod; Chris Patten; Oxana Polyakova; Cecil E Rise; Martin Rüdiger; Robert J Sheppard; Daniel J Slade; Pamela Thomas; Jim Thorpe; Gang Yao; Gerard Drewes; Denisa D Wagner; Paul R Thompson; Rab K Prinjha; David M Wilson
Journal:  Nat Chem Biol       Date:  2015-01-26       Impact factor: 15.040

Review 9.  It Takes Two to Tango: How a Dysregulation of the Innate Immunity, Coupled With Candida Virulence, Triggers VVC Onset.

Authors:  Andrea Ardizzoni; Robert T Wheeler; Eva Pericolini
Journal:  Front Microbiol       Date:  2021-06-07       Impact factor: 6.064

10.  Farm Exposure as a Differential Risk Factor in ANCA-Associated Vasculitis.

Authors:  P Willeke; B Schlüter; C Sauerland; H Becker; S Reuter; A Jacobi; H Schotte
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.